Trial Profile
A study with cell therapy treatment (Megadose Drug Combination) to significantly reduce the need for immune suppression treatment for both donor-matched and mismatched bone marrow transplant patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Megadose drug combination Cell Source (Primary)
- Indications Bone marrow transplant rejection; Engraftment
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2015 New trial record
- 11 Nov 2015 According to a Cell Source media release, the first patient has been treated in this study.